CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT — Stella

Recruiting

Back to B ALL trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Peking University People's Hospital, Beijing, China

Key details

Phase

Large-scale testing

Sponsor

Peking University People's Hospital

Enrollment target

~70 participants

Started

November 2025

Primary completion

December 2027

Age range

3 Years – 79 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov